TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1α degradation

被引:97
作者
Amelio, Ivano [1 ]
Inoue, Satoshi [2 ]
Markert, Elke K. [3 ]
Levine, Arnold J. [3 ]
Knight, Richard A. [1 ]
Mak, Tak W. [2 ]
Melino, Gerry [1 ,4 ]
机构
[1] MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England
[2] Univ Hlth Network, Ontario Canc Inst, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada
[3] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA
[4] Univ Roma Tor Vergata, Biochem Ist Dermopat, Immacolata Lab, Dept Expt Med & Surg, I-00133 Rome, Italy
基金
英国医学研究理事会;
关键词
p73; p53; family; tumor progression; VEGF; tumor vascularization; SUPPRESSOR FUNCTIONS; P73; P53; MUTANT; MICE; O-2; PATHWAY; TARGETS;
D O I
10.1073/pnas.1410609111
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumor hypoxia and hypoxia-inducible factor 1 (HIF-1) activation are associated with cancer progression. Here, we demonstrate that the transcription factor TAp73 opposes HIF-1 activity through a nontranscriptional mechanism, thus affecting tumor angiogenesis. TAp73-deficient mice have an increased incidence of spontaneous and chemically induced tumors that also display enhanced vascularization. Mechanistically, TAp73 interacts with the regulatory subunit (alpha) of HIF-1 and recruits mouse double minute 2 homolog into the protein complex, thus promoting HIF-1 alpha polyubiquitination and consequent proteasomal degradation in an oxygen-independent manner. In human lung cancer datasets, TAp73 strongly predicts good patient prognosis, and its expression is associated with low HIF-1 activation and angiogenesis. Our findings, supported by in vivo and clinical evidence, demonstrate a mechanism for oxygen-independent HIF-1 regulation, which has important implications for individualizing therapies in patients with cancer.
引用
收藏
页码:226 / 231
页数:6
相关论文
共 27 条
[1]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[2]   The evolution of the cancer niche during multistage carcinogenesis [J].
Barcellos-Hoff, Mary Helen ;
Lyden, David ;
Wang, Timothy C. .
NATURE REVIEWS CANCER, 2013, 13 (07) :511-518
[3]   ACCUMULATION OF P53 IN A MUTANT-CELL LINE DEFECTIVE IN THE UBIQUITIN PATHWAY [J].
CHOWDARY, DR ;
DERMODY, JJ ;
JHA, KK ;
OZER, HL .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (03) :1997-2003
[4]   Cooperative interaction of hypoxia-inducible factor-2α (HIF-2α) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1) [J].
Elvert, G ;
Kappel, A ;
Heidenreich, R ;
Englmeier, U ;
Lanz, S ;
Acker, T ;
Rauter, M ;
Plate, K ;
Sieweke, M ;
Breier, G ;
Flamme, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :7520-7530
[5]  
Filler RB, 2007, CSH PROTOC, V2007
[6]   Tumor predisposition in mice mutant for p63 and p73:: Evidence for broader tumor suppressor functions for the p53 family [J].
Flores, ER ;
Sengupta, S ;
Miller, JB ;
Newman, JJ ;
Bronson, R ;
Crowley, D ;
Yang, A ;
McKeon, F ;
Jacks, T .
CANCER CELL, 2005, 7 (04) :363-373
[7]   INDUCTION OF ANGIOGENESIS DURING THE TRANSITION FROM HYPERPLASIA TO NEOPLASIA [J].
FOLKMAN, J ;
WATSON, K ;
INGBER, D ;
HANAHAN, D .
NATURE, 1989, 339 (6219) :58-61
[8]   Two sequence motifs from HIF-1α bind to the DNA-binding site of p53 [J].
Hansson, LO ;
Friedler, A ;
Freund, S ;
Rüdiger, S ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) :10305-10309
[9]  
Harris AL, 2002, NAT REV CANC
[10]   The ubiquitin system [J].
Hershko, A ;
Ciechanover, A .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :425-479